Cancer Drugs Granted Breakthrough Therapy Designation in China

The findings of this cross-sectional study suggest that BTD has facilitated faster time to market for cancer drugs and improved novelty, but the price of ...

Sunvozertinib Receives Breakthrough Therapy Designation for ...

China's CDE has granted breakthrough therapy designation to first ... Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in ...

LBL-024 Receives Breakthrough Therapy Designation in China for ...

The Center for Drug Evaluation of China's National Medical Products Administration has granted breakthrough therapy designation to LBL-024 ...

Blenrep (belantamab mafodotin) in combination receives ... - GSK

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Breakthrough Therapy Designation in China underscores the ...

Sunvozertinib Granted Breakthrough Therapy Designation by China ...

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 ...

HUTCHMED Receives Breakthrough Therapy Designation in China ...

Savolitinib is marketed in China under the brand name ORPATHYS® for the treatment of patients with non-small cell lung cancer (“NSCLC”) with MET exon 14 ...

Bayer receives Breakthrough Therapy designation in China for BAY ...

1. Siegel F, Karsli-Uzunbas G, Kotynkova K, et al, Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer. · 2. Siegel F, ...

Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs ...

Importance: The China National Drug Administration (NMPA) established the breakthrough therapy designation (BTD) in 2020 to encourage the ...

Assessment of the breakthrough-therapy-designated drugs granted ...

The implementation of China's breakthrough therapy designation (BTD) program in 2020 to accelerate drug development for serious or ...

9MW2821 granted breakthrough therapy designation in China for ...

With this designation, the development process for 9MW2821 can benefit from prioritized engagement with China's Center for Drug Evaluation as ...

Zai Lab Announces Breakthrough Therapy Designation Granted for ...

Today's recognition further supports repotrectinib as a potential first-in-class treatment for patients with NTRK-positive, TKI-pretreated solid ...

The Breakthrough Therapy Designation in China

The Breakthrough Therapy Designation intends to expedite the evaluation of medicines for critical diseases for which there are no recognized treatments.

Jacobio Pharma Announces Breakthrough Therapy Designation ...

Pancreatic cancer is glecirasib's second BTD indication in China. In December 2022, gleciracib was granted BTD for the second line setting and ...

GSK Blenrep granted Breakthrough Therapy Designation by China's ...

Granted based on results from phase III head-to-head DREAMM-7 trial · Designation expedites development of investigational drugs with potential ...

Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs ...

Request PDF | Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, ...

Amgen Announces Breakthrough Therapy Designation Granted For ...

The designation is for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who ...

Endometrial cancer drug gets breakthrough therapy designation

HUTCHMED has announced that the NMPA has granted Breakthrough Therapy Designation for its advanced endometrial cancer treatment.

Breakthrough Therapy Designation - HUTCHMED

HUTCHMED receives breakthrough therapy designation in China for fruquintinib combination with sintilimab for treatment of advanced endometrial cancer.

Zai Lab Announces Breakthrough Therapy Designation Granted for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that the · Center for Drug ...

Jacobio Pharma Announces Breakthrough Therapy Designation ...

Pancreatic cancer is glecirasib's second BTD indication in China. In December 2022, gleciracib was granted BTD for the second line setting and ...